EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD)

Felician Stancioiu iD, Raluca Bogdan, Radu Dumitrescu iD

Life · 13.08.2023 · 13 (8) · 1736

DOI: 10.3390/life13081736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 13.08.2023. Verfasst von Felician Stancioiu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fundatia Bio-Forum, 040245 Bucharest, Romania. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autistic spectrum disease (ASD) is an increasingly common diagnosis nowadays with a prevalence of 1–2% in most countries. Its complex causality—a combination of genetic, immune, metabolic, and environmental factors—is translated into pleiomorphic developmental disorders of various severity, which have two main aspects in common: repetitive, restrictive behaviors and difficulties in social interaction varying from awkward habits and verbalization to a complete lack of interest for the outside world. The wide variety of ASD causes also makes it very difficult to find a common denominator—a disease biomarker and medication—and currently, there is no commonly used diagnostic and therapeutic strategy besides clinical evaluation and psychotherapy. In the CORDUS clinical study, we have administered autologous cord blood to ASD kids who had little or no improvement after other treatments and searched for a biomarker which could help predict the degree of improvement in each patient. We have found that the neuron-specific enolase (NSE) was elevated above the normal clinical range (less than 16.3 ng/mL) in the vast majority of ASD kids tested in our study (40 of 41, or 97.5%). This finding opens up a new direction for diagnostic confirmation, dynamic evaluation, and therapeutic intervention for ASD kids.

Schlagwörter

Stichwörter der Autor:innen

autismautism biomarkerautistic spectrum disease (ASD)mTORneuroinflammationneuron-specific enolase (NSE)neuronal apoptosis

Autor:innen und Institutionen

  • Fundatia Bio-Forum, 040245 Bucharest, Romania.
  • Medicover Hospital Bucharest, 013982 Bucharest, Romania.

ORCID-Profile: Felician Stancioiu, Radu Dumitrescu

Zitieren

APA

Stancioiu, F., Bogdan, R., & Dumitrescu, R. (2023). Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD). Life, 13(8), 1736. https://doi.org/10.3390/life13081736

Vancouver

Stancioiu F, Bogdan R, Dumitrescu R. Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD). Life. 2023;13(8):1736. doi:10.3390/life13081736

BibTeX
@article{Stancioiu2023,
  author = {Stancioiu, Felician and Bogdan, Raluca and Dumitrescu, Radu},
  title = {Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD)},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {8},
  pages = {1736},
  doi = {10.3390/life13081736}
}
Kostenlos starten →